Compare TGLS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | OGN |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2011 | 2020 |
| Metric | TGLS | OGN |
|---|---|---|
| Price | $37.67 | $13.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $55.75 | $11.25 |
| AVG Volume (30 Days) | 333.1K | ★ 2.0M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.63% | 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.27 | 0.95 |
| Revenue | $370,984,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $11.39 | $2.51 |
| P/E Ratio | $28.95 | ★ $14.46 |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $34.05 | $5.69 |
| 52 Week High | $63.46 | $13.83 |
| Indicator | TGLS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 56.01 |
| Support Level | $37.43 | $13.46 |
| Resistance Level | $46.99 | $13.77 |
| Average True Range (ATR) | 1.34 | 0.04 |
| MACD | 0.43 | 0.00 |
| Stochastic Oscillator | 78.08 | 50.00 |
Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.